Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases

Research output: Contribution to journalArticle

Abstract

Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80% of invasive disease and represent approximately 60% of middle-ear isolates in children younger than age 2 years; the majority of penicillin-resistant strains are confined to these same few serogroups. Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in preventing invasive disease in adults, these vaccines fail to protect against otitis media or nasopharyngeal carriage and are poorly immunogenic in children younger than age 2 years. A new generation of pneumococcal vaccines has been developed, linking the capsular polysaccharide of seven to 11 serotypes to a protein carrier. The only pneumococcal vaccine approved to date for children younger than age 2 years is a seven-valent conjugate vaccine (PnCRM-7) (Prevnar; Wyeth Vaccines, Pearl River, New York), which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against vaccine-type invasive disease and 50-60% effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.

Original languageEnglish (US)
Pages (from-to)634-644
Number of pages11
JournalAmerican Journal of Epidemiology
Volume159
Issue number7
DOIs
StatePublished - Apr 1 2004

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Pediatrics
Vaccines
Otitis Media
Middle Ear
Rivers
Penicillins
Polysaccharides
Immunization
Carrier Proteins
Morbidity
Costs and Cost Analysis
Mortality
Serogroup

Keywords

  • Child
  • Communicable diseases
  • Immunization
  • Pneumococcal diseases
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Epidemiology

Cite this

@article{fbca2b9616e84bbf9ea15f207f2723c6,
title = "Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases",
abstract = "Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80{\%} of invasive disease and represent approximately 60{\%} of middle-ear isolates in children younger than age 2 years; the majority of penicillin-resistant strains are confined to these same few serogroups. Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in preventing invasive disease in adults, these vaccines fail to protect against otitis media or nasopharyngeal carriage and are poorly immunogenic in children younger than age 2 years. A new generation of pneumococcal vaccines has been developed, linking the capsular polysaccharide of seven to 11 serotypes to a protein carrier. The only pneumococcal vaccine approved to date for children younger than age 2 years is a seven-valent conjugate vaccine (PnCRM-7) (Prevnar; Wyeth Vaccines, Pearl River, New York), which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100{\%} effective against vaccine-type invasive disease and 50-60{\%} effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.",
keywords = "Child, Communicable diseases, Immunization, Pneumococcal diseases, Streptococcus pneumoniae",
author = "O'Brien, {Katherine L} and Mathuram Santosham",
year = "2004",
month = "4",
day = "1",
doi = "10.1093/aje/kwh082",
language = "English (US)",
volume = "159",
pages = "634--644",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases

AU - O'Brien, Katherine L

AU - Santosham, Mathuram

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80% of invasive disease and represent approximately 60% of middle-ear isolates in children younger than age 2 years; the majority of penicillin-resistant strains are confined to these same few serogroups. Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in preventing invasive disease in adults, these vaccines fail to protect against otitis media or nasopharyngeal carriage and are poorly immunogenic in children younger than age 2 years. A new generation of pneumococcal vaccines has been developed, linking the capsular polysaccharide of seven to 11 serotypes to a protein carrier. The only pneumococcal vaccine approved to date for children younger than age 2 years is a seven-valent conjugate vaccine (PnCRM-7) (Prevnar; Wyeth Vaccines, Pearl River, New York), which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against vaccine-type invasive disease and 50-60% effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.

AB - Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80% of invasive disease and represent approximately 60% of middle-ear isolates in children younger than age 2 years; the majority of penicillin-resistant strains are confined to these same few serogroups. Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in preventing invasive disease in adults, these vaccines fail to protect against otitis media or nasopharyngeal carriage and are poorly immunogenic in children younger than age 2 years. A new generation of pneumococcal vaccines has been developed, linking the capsular polysaccharide of seven to 11 serotypes to a protein carrier. The only pneumococcal vaccine approved to date for children younger than age 2 years is a seven-valent conjugate vaccine (PnCRM-7) (Prevnar; Wyeth Vaccines, Pearl River, New York), which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against vaccine-type invasive disease and 50-60% effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.

KW - Child

KW - Communicable diseases

KW - Immunization

KW - Pneumococcal diseases

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=1642502987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642502987&partnerID=8YFLogxK

U2 - 10.1093/aje/kwh082

DO - 10.1093/aje/kwh082

M3 - Article

VL - 159

SP - 634

EP - 644

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 7

ER -